Cancer's Other Half: Limiting Metastasis by Restricting Blood Vessel Formation
ISEF · 2019 Biomedical and Health Sciences Third Award
Overview
Cancer has two halves: malignant cells that initiate oncogenesis, and cancer stromal cells that form the tumor microenvironment. Isocitrate dehydrogenases (IDHs) are enzymes in normal cellular metabolism. Cells with IDH mutations produce 2-hydroxyglutarate (2HG), and 2HG directly transforms normal cells to malignant cells through histone demethylation. However, whether IDH mutations affect cancer stromal cells is elusive. I hypothesized that the IDH-mutant cancer secretome would stimulate oncogenic vascular genesis. First, I isolated IDH-mutant fibrosarcoma secretome and treated vascular-endothelial cells. The IDH-mutant cancer secretome stimulated vascular tube formation by ~138% relative to control, by quantitative NIH/Image J analysis and statistical comparisons, suggesting that IDH-mutant tumors may metastasize by stimulating angiogenesis. Then, I followed up with an additional question of whether GSK864, a small-molecule allosteric IDH inhibitor, would attenuate vascular genesis. Remarkably, GSK864 attenuated vascular formation by ~36%, relative to the control, suggesting a potential to reduce metastasis of IDH-mutant cancers. Furthermore, I asked another question of whether 2HG, an IDH-mutant oncometabolite, would specifically stimulate angiogenesis. Indeed, 2HG not only reversed GSK864 attenuation, but also significantly stimulated vascular genesis in the GSK864-treated cancer secretome. Finally, I performed yet another experiment, and found that exogenous 2HG alone stimulated vascular genesis, identifying 2HG as a key culprit of oncogenesis angiogenesis and thus a therapeutic target. These findings suggest novel mechanisms by which the IDH-mutant cancer secretome and/or metabolite, specifically 2HG, induces oncogenic angiogenesis and metastasis.
Awards (1)
- Third Award of $1,000 $1,000
Competition history
- ISEF 2019
Resources
Related projects
ISEF · 2020
Expression of c-MYC in Human Endothelial Cells Results in Abnormal Vascular Morphogenesis and Metabolic Reprogramming
ISEF · 2017
Exploiting Migration and Metabolism: A Novel Approach to Metastatic Cancers
ISEF · 2023
Refining the Analysis and Tracking of Cell Behavior to Improve Understanding on How Metabolites Impact Glioblastoma Cell Lines
ISEF · 2026
Identification of a Novel TBX2-Dependent Mechanism Linking Pericyte Dynamics to Abnormal Vasculature in Lung Adenocarcinoma
ISEF · 2020
Stranger Danger: A Novel Approach to Cancer Research Using Morphing -- The Correlation between Intercellular Transfer from Cancer-Associated Fibroblasts and Metastatic Capacity, Proliferation Rate and Phenotype of Osteosarcoma Cells
ISEF · 2018
Cutting off Cancer: Design, Analysis, and Synthesis of Novel Vascular Disrupting Agents
ISEF · 2026
The Role of VEGF and FGF21 in Restoring the Hypotrophic Response of Endostatin in Neonatal Rat Ventricular Myocytes
ISEF · 2018
Examining the Effect of HIF and Notch in Endothelial Cell Migration and Sprouting
Closest projects by meaning, across every fair and year in the corpus.
Browse more like this
Source: Regeneron International Science and Engineering Fair